Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Ocular Therapeutix Inc (NASDAQ: OCUL) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Ocular Therapeutix Inc (NASDAQ: OCUL)  concerning whether a series of statements by Ocular Therapeutix Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 25, 2016, Ocular Therapeutix revealed that the U.S. Food and Drug Administration ("FDA") had denied approval for the Company's treatment of post-operative eye pain. The Company stated that the FDA raised concerns related to its manufacturing process after an inspection of its facility.

Following this news, Ocular Therapeutix share price has dropped as much as $0.54, or 10.44%, to $4.63 during intraday trading on July 25, 2016.

Based in Bedford, Massachusetts, and founded in 2006 Ocular Therapeutix Inc focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.

If you purchased shares of Ocular Therapeutix Inc (NASDAQ: OCUL) on or before July 25, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185